REST stands for "Revosyl, Efficacy, Safety & Tolerability"
REST is an Observational Study on the Efficacy, Safety and Tolerability of Revosyl in Managing Patients with Essential Hypertension in Actual Practice in Syria.
Clinical trials of different types have shown clearly that high blood pressure is associated with increased cardiovascular morbidity and mortality, and lowering high blood pressure reduces these complications, mainly, heart failure, myocardial infarction & stroke. Suppression of the Renin-Angiotensin Aldestrone System (RAAS) by means of Angiotensin Converting Enzyme (ACE) inhibitors has been employed successfully for long time in the treatment of essential hypertension.
Previous studies with Perindopril / Coversylâ„?have been conducted on patients with hypertension but no large scale study has been conducted on Perindopril produced by National Pharmaceutical Company in Syria. Controlled clinical trials cannot provide data which reflect actual real life usage of the drug. This is an observational, prospective, open label, post marketing, non interventional drug monitoring program to collect data on the usage of Revosylâ„?in daily medical practice conditions in Syria and in line with the current applicable local laws.
This Study aims at evaluating efficacy, safety and tolerability of Revosyl
® (Ibn-Alhaytham) given as monotherapy or as a part of a combination regimen with other antihypertensive agents in management of patients with essential hypertension as per actual medical practice in Syria.
Prior to participation in the study,
Ibn-Alhaytham Pharmaceutical Industry cardiovascular line -medical representatives will visit the selected physicians for signing up a participation agreement stating physician's approval to conduct the study according to the plans provided by
Ibn-Alhaytham Pharmaceutical Industry �Scientific Department and to provide the company with the case report form for each patient after study completion.
For more information about the study check the
REST Protocol